Thinking around abdominal obesity and cardiovascular risk.
Obesity, particularly intra-abdominal (visceral) obesity, is a leading cause of cardiovascular disease (CVD), insulin resistance, type 2 diabetes, dyslipidaemia, inflammation and thrombosis. A useful indicator for visceral fat is waist circumference, which is associated with all-cause mortality. Pro-inflammatory adipokines play a causal role in the development of pathologies associated with insulin resistance, type 2 diabetes and CVD. In addition to established anti-obesity therapies, namely orlistat and sibutramine, a new type of agent that inhibits the cannabinoid receptor (CB1) is advanced in development to reduce appetite and act predominantly against intra-abdominal adiposity.
BROOM, I. 2006. Thinking around abdominal obesity and cardiovascular risk. British journal of diabetes and vascular disease, 6(2), pages 58-61.
|Journal Article Type||Article|
|Acceptance Date||Mar 31, 2006|
|Online Publication Date||Mar 31, 2006|
|Publication Date||Mar 31, 2006|
|Deposit Date||Dec 6, 2012|
|Publicly Available Date||Dec 6, 2012|
|Journal||British journal of diabetes and vascular disease|
|Peer Reviewed||Peer Reviewed|
|Keywords||Abdominal obesity; Metabolic syndrome; Visceral fat; Waist circumference; Cardiometabolic risk|
BROOM 2006 Current thinking around abdominal
Publisher Licence URL
You might also like
Practices of food and diet in an urban context.
Weight loss and ethnicity: a cohort study of the effects induced by a very low calorie diet.
Homo Adipatus: a new species: weight management, treatment and prevention.
Low-carbohydrate diets, obesity and type 2 diabetes: a review.